Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study
- 12 September 2017
- journal article
- research article
- Published by Elsevier BV in The Lancet Haematology
- Vol. 4 (10), e475-e486
- https://doi.org/10.1016/s2352-3026(17)30171-0
Abstract
No abstract availableKeywords
Funding Information
- Celgene
This publication has 33 references indexed in Scilit:
- Minimal residual disease is an independent predictor for 10-year survival in CLLBlood, 2016
- An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient dataThe Lancet Oncology, 2016
- Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemiaBlood, 2014
- Prediction of poor outcome in CLL patients following first-line treatment with fludarabine, cyclophosphamide and rituximabLeukemia, 2013
- Sequential Therapy With Fludarabine, High-Dose Cyclophosphamide, and Rituximab in Previously Untreated Patients With Chronic Lymphocytic Leukemia Produces High-Quality Responses: Molecular Remissions Predict for Durable Complete ResponsesJournal of Clinical Oncology, 2009
- Consolidation and maintenance rituximab therapy in chronic lymphocytic leukemiaCurrent Oncology Reports, 2008
- Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemiaBlood, 2006
- Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemiaBlood, 2005
- Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged SurvivalJournal of Clinical Oncology, 2005
- Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapyBlood, 2001